Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis

NCT ID: NCT02178306

Last Updated: 2014-06-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-09-30

Brief Summary

To evaluate the safety and efficacy, in particular with regard to renal function of telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to endstage renal impairment after 12 weeks of treatment

Conditions

Hypertension

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Telmisartan

Group Type: EXPERIMENTAL

Telmisartan low dose

Intervention Type: DRUG

Telmisartan high dose

Intervention Type: DRUG

patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment

Placebo

Intervention Type: DRUG

Run-in phase

Interventions

Telmisartan low dose

Intervention Type: DRUG

Telmisartan high dose

patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment

Intervention Type: DRUG

Placebo

Run-in phase

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Mild to moderate hypertension, sitting diastolic BP ≥ 90 mmHg and BP ≤ 109 mmHg at visit 2

2. No increase of serum creatinine over 30% within 6 months before the trial

3. Stable renal insufficiency with a serum creatinine between 200 and 600 µmol/l or maintenance of hemodialysis

4. Stable proteinuria of at least 500 mg/24h

5. No change in hemodialysis regimen within the last two months prior to visit 1

6. 18 years of age or more

7. Ability to provide written informed consent in accordance with good clinical practice and local registration

8. Able to stop current antihypertensive therapy (ACE-Inhibitors or angiotensin II receptor subtype 1- Blocker) without risk to the patient

Exclusion Criteria

1. Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in-phase) who:

1. are not surgically sterile; and/or

2. are nursing

3. are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include oral, implantable or injectable contraceptives

2. Known or suspected renovascular hypertension

3. Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥110 mmHg during any visit of the placebo run-in phase

4. Hepatic dysfunction as defined by the following laboratory parameters:

serum glutamate pyruvate transaminase (ALT) or serum glutamate oxaloacetate transaminase (AST) > than 2 times the upper limit of normal range

5. Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients postrenal transplant or with only one kidney

6. Clinically relevant hypo- or hyperkalaemia

7. Uncorrected volume depletion

8. Uncorrected sodium depletion

9. Primary aldosteronism

10. Hereditary fructose intolerance

11. Biliary obstructive disorders

12. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II antagonists

13. History of drug or alcohol abuse within 6 months

14. Chronic administration of any medications known to affect blood pressure, except medication allowed by the protocol (ß-blocker, alpha-blocker, calcium antagonists, clonidine, minoxidil, and diuretics)

15. Any investigational therapy within one month of signing the informed consent form

16. Known hypersensitivity to any component of the formulation

17. Has no contra-indication to a placebo run-in period (e.g. unstable angina within the past 3 months, stroke within the past 6 months or myocardial infarction or cardiac surgery within the past 3 months)

18. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan

19. Compliance < 70% during run-in period (defined by pill count)

20. History of heart failure, malignancy, or any disorders requiring immunosuppressive therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

502.339

Identifier Type: -

Identifier Source: org_study_id